Pharmaceuticals News and Research

RSS

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

1 Mar 2013

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).

1 Mar 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

At the Faculty of Pharmacy of the Basque Public University (UPV/EHU) the Pharmacokinetics, Nanotechnology and Gene Therapy research team is using nanotechnology to develop new formulations that can be applied to drugs and gene therapy.

1 Mar 2013

UT Arlington receives new $7.5 million gift from Shimadzu Scientific Instruments

A new $7.5 million gift from Shimadzu Scientific Instruments to The University of Texas at Arlington will support one of the most significant installments of advanced scientific equipment in the United States, propelling the University to new heights of discovery and innovation.

1 Mar 2013

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

28 Feb 2013

U-M to study how exercise, other therapies might work differently in lean and obese individuals

Researchers at the University of Michigan School of Kinesiology have received a $1 million grant to study how exercise and other therapies might work differently in lean and obese individuals.

28 Feb 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Wyss Founding Director receives NC3Rs 3Rs Prize for Lung-on-a-Chip

In a London ceremony today, Wyss Founding Director Don Ingber, M.D., Ph.D., received the NC3Rs 3Rs Prize from the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) for his innovative Lung-on-a-Chip -- a microdevice lined by human cells that recapitulates complex functions of the living lung.

28 Feb 2013

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

27 Feb 2013

Global eye health company, Bausch + Lomb, names Robert Bertolini as president and chief financial officer

Bausch + Lomb, the global eye health company, has named Robert Bertolini as president and chief financial officer effective immediately. In this capacity, he will oversee the company's Finance, Information Technology and Global Quality and Operations (GQO) functions. Bertolini, who assumes CFO responsibilities from Brian J. Harris, will report to Bausch + Lomb's chief executive officer, Brent Saunders.

27 Feb 2013

Cliantha Research chooses Acceliant's eClinical Suite for clinical trial data management needs

Acceliant, a global technology provider of innovative clinical trial data management solutions, today announced that Cliantha Research, a leading global Contract Research Organization, has chosen Acceliant's eClinical Suite for their clinical trial data management needs.

27 Feb 2013

Ampio Pharmaceuticals starts Optina clinical trial

Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.

27 Feb 2013

Smoking prevention and cessation campaigns: an interview with Dr DePinho, University of Texas MD Anderson Cancer Center and Dr Mohar, National Cancer Institute of Mexico

There are more than 94 million former and current smokers in the United States, and more than 21 million in Mexico, according to the 2009 Global Adult Tobacco Survey (GATS) Fact Sheet.

27 Feb 2013

Survey: Medical students still receive free meals and gifts from pharmaceutical companies

A first-of-its kind national survey of medical students and residents finds that despite recent efforts by medical schools and academic medical centers to restrict access of pharmaceutical sales representatives to medical trainees, medical students and residents still commonly receive meals, gifts, and industry-sponsored educational materials.

27 Feb 2013

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.

27 Feb 2013

Bridging the Divides model can help patients with chronic heart disease

Christiana Care Health System has partnered with ColdLight and Medecision to provide more coordinated personalized care to patients with chronic heart disease with breakthrough analytics technology.

27 Feb 2013

MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

Huntington's disease, also known as Huntington's chorea, is a hereditary brain disease causing movement disorders and dementia. In Germany, there are about 8,000 patients affected by Huntington's disease, with several hundred new cases arising every year. The disease usually manifests between the ages of 35 and 50.

27 Feb 2013

IFR, PBL to further develop Dynamic Gastric Model

The Dynamic Gastric Model, developed from years of research at the Institute of Food Research, has taken significant steps towards improving its commercial use by food and drug companies worldwide.

26 Feb 2013

Two discriminating biological markers found to predict a favorable response to treatment in triple-negative breast cancer

Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the identification of two discriminating biological marker candidates which are indicative of a favorable response to treatment in women suffering from triple-negative breast cancer (TNBC).

26 Feb 2013

Pharmaceuticals News and Research

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

UT Arlington receives new $7.5 million gift from Shimadzu Scientific Instruments

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

U-M to study how exercise, other therapies might work differently in lean and obese individuals

EpiCept fourth quarter revenue decreases to $0.1 million

Wyss Founding Director receives NC3Rs 3Rs Prize for Lung-on-a-Chip

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Global eye health company, Bausch + Lomb, names Robert Bertolini as president and chief financial officer

Cliantha Research chooses Acceliant's eClinical Suite for clinical trial data management needs

Ampio Pharmaceuticals starts Optina clinical trial

Smoking prevention and cessation campaigns: an interview with Dr DePinho, University of Texas MD Anderson Cancer Center and Dr Mohar, National Cancer Institute of Mexico

Survey: Medical students still receive free meals and gifts from pharmaceutical companies

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Bridging the Divides model can help patients with chronic heart disease

MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

IFR, PBL to further develop Dynamic Gastric Model

Two discriminating biological markers found to predict a favorable response to treatment in triple-negative breast cancer

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence